Jayne D, et al. - In this double-blind, placebo-controlled, multicenter study, 105 individuals were examined to assess the safety and effectiveness of belimumab as adjunctive therapy to maintain the remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). They observed no reduction of protocol-specified event (PSE) risk or vasculitis relapse with belimumab therapy. Overall PSE rate was also noticed lower in belimumab as compared to placebo. They recorded 92.5% of cases with adverse events in belimumab treatment. They concluded no remission in risk of relapse with belimumab plus azathioprine and glucocorticoids as all vasculitis relapses in the belimumab group were in cyclophosphamide-induced, anti-PR3-ANCA-associated cases.